ArticleScientific reports2019
Red Blood Cell Membrane Bioengineered Zr-89 Labelled Hollow Mesoporous Silica Nanosphere for Overcoming Phagocytosis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Membrane-modified mesoporous silica nanoparticles guided by tumor immunomodulatory regulation for anti-tumor strategies.Frontiers in immunology · 2026Review
- Nanomedicines for the treatment of genitourinary neoplasms.Materials today. Bio · 2025Review
- Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.Journal of nanobiotechnology · 2024Review
- Artificial blood for therapeutic and laboratory usage: Where do we stand?Biomicrofluidics · 2024Review
- Long-Term Tumor-Targeting Effect ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Artificial cells for in vivo biomedical applications through red blood cell biomimicry.Nature communications · 2024Review
- The blood-brain barrier: structure, regulation, and drug delivery.Signal transduction and targeted therapy · 2023Review
- Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.Scientific reports · 2023Article
- Construction and In Vitro Evaluation of a Tumor Acidic pH-Targeting Drug Delivery System Based onBioengineering (Basel, Switzerland) · 2022Article
- Latest Advances in Biomimetic Cell Membrane-Coated and Membrane-Derived Nanovectors for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics.Materials today. Bio · 2022Article
- Research update on cell membrane camouflaged nanoparticles for cancer therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Functionalized Erythrocyte Membrane-Coated Nanoparticles for the Treatment ofFrontiers in microbiology · 2022Article
- Cell Membrane Vesicles with Enriched CXCR4 Display Enhances Their Targeted Delivery as Drug Carriers to Inflammatory Sites.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Biosafety of mesoporous silica nanoparticles: a combined experimental and literature study.Journal of materials science. Materials in medicine · 2021Article
- Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation timeAsian journal of pharmaceutical sciences · 2021Review
- Synthesis of Zr-89-Labeled Folic Acid-Conjugated Silica (SiOMaterials (Basel, Switzerland) · 2021Article
- Tumor Targeting Effect of Triphenylphosphonium Cations and Folic Acid Coated with Zr-89-Labeled Silica Nanoparticles.Molecules (Basel, Switzerland) · 2020Article
- Guest Edited Collection: Radioisotopes and radiochemistry in health science.Scientific reports · 2020Article
- Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomimetic nanoparticles (NPs) have been actively studied for their biological compatibility due to its distinguished abilities viz. long-term circulation, low toxicity, ease for surface modification, and its ability to avoid phagocytosis of NPs by macrophages. Coating the NPs with a variety of cell membranes bearing the immune control proteins increases drug efficacy while complementing the intrinsic advantages of the NPs. In this study, efforts were made to introduce oxophilic radiometal
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.